Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Design of synthetic peptides for oral vaccination

R.H. Meloen*

Institute for Animal Science and Health (ID-DLO), Edelhertweg 15, NL-8219 PH Lelystad, The Netherlands

Accepted June 1995

Abstract

The rational design of effective oral vaccines based on synthetic peptides is a very ambitious undertaking, and involves the solution of huge problems related to protection of the antigens against degradation in the alimentary tract, efficient uptake of the antigens by the relevant cells, and efficient induction of long lasting systemic immunity, local immunity, or both. This paper summarises the steps, necessary to develop such synthetic oral vaccines. These steps involve: (1) the definition of B-cell epitopes; (2) the definition of T-cell epitopes; (3) definition of the carrier or backbone molecule; (4) definition of an immunomodulating element; (5) definition of an adjuvant element; and (6) definition of a targeting element. Good progress is being made with respect to the first three steps, the other steps still provide major challenges, notably the definition of targeting elements. Nevertheless, the first synthetic oral vaccines may become reality in the near future, depending on the speed by which new technology in the area of molecular recognition will develop, i.e. the appropriate chemistry, organic chemistry, molecular modelling, resolution of the molecular interaction of key molecules in microbiology and immunology.

Keywords: Synthetic peptide; Oral vaccine; Drug design

Contents

1. Introduction .......................................................... 91
2. Definition of the elements of a synthetic oral vaccine ............................................. 92
  2.1. Definition of B-cell epitopes ............................................................................. 93
  2.2. Definition of T-cell epitopes ............................................................................. 95
  2.3. Definition of the carrier or backbone molecule ............................................. 95
  2.4. Definition of the immunomodulating element ............................................. 95
  2.5. Definition of the adjuvant element ................................................................ 95
  2.6. Definition of a targeting element .................................................................. 96
3. Conclusion ......................................................................................... 96
Acknowledgements ....................................................................................... 96
References ...................................................................................................... 96

1. Introduction

The ultimate vaccine for human use will be an oral vaccine which is cheap, stable, induces long-
lasting immunity against a spectrum of diseases after a single application. Development of such a vaccine is extremely ambitious and not yet feasible because necessary data and technology is lacking. However, less ambitious undertakings, for instance the development of a synthetic oral vaccine against a single disease which is stable and does not require a “cold chain” would already revolutionize vaccination programs, especially in the developing countries. Such vaccines would negate the need for trained medical personnel and the need to use syringes, which in itself, poses a considerable health risk.

If oral vaccination is used as an alternative for parenteral vaccination then the target would be to establish, in addition to local immunity, systematic immunity [1]. In this paper I limit myself to the possibilities to develop synthetic oral vaccines. Oral vaccines based on live carrier systems, for instance Salmonella typhimurium [2] may be equally effective and are probably closer to realization, however they are beyond the scope of this contribution.

Development of effective synthetic oral vaccines has to take into account three aspects, which are special to this route of application: (1) the antigen should be sufficiently protected from the harsh environment to which it is exposed in the alimentary tract, i.e., extreme differences in pH and the abundance of proteolytic enzymes; (2) due to the large surface of the epithelium of the alimentary tract the antigen should be precisely targeted towards the entry point of the gut associated immune system in order to prevent the need for unrealistic high vaccine doses; and (3) due to the inherent low responsiveness of the gut associated immune system the antigen should be properly adjuvanted. When effective systemic immunity is needed in addition to local immunity, appropriate immunomodulation may be required as well.

To address these aspects properly two basic strategies can be used (Fig. 1). Both strategies are based on delivering molecules carrying a combination of basic functions towards the appropriate site in the gut, i.e. the M cells of the Peyers patches.

One strategy is based on the delivery of the “naked” molecule which is harnessed against the environment, the other strategy is based on delivery of the molecule or molecules shielded from the environment by encapsulation. Both strategies are different and one has to decide at an early stage which one should be followed.

The functions or elements that are combined to form an effective oral vaccine are the following (they are the same in both strategies, however differently combined):

1. definition of the appropriate B-cell epitopes
2. definition of the appropriate T-cell epitopes
3. definition of the carrier or backbone molecule
4. definition of an immunomodulating element
5. definition of an adjuvant element
6. definition of a targeting element

Definition of each element is highly dependent on the strategy that is being followed. If the naked molecule strategy is followed, the whole synthetic molecule, including the epitopes, must be resistant to the environment; this can be

---

**Fig. 1. Two strategies to develop oral vaccines.** Strategy A is based on the use of all necessary elements combined into one molecule. Strategy B is based on delivering all necessary elements in an encapsulated form. In contrast to strategy A, a targeting device may not be necessary, because the encapsulated particles, depending on their physical-chemical properties, will be taken up spontaneously by the target cells.
effected using non-natural building blocks, for instance D-amino acids. The consequence is that the epitopes should be mapped using the same building blocks.

Furthermore, the relative high number of elements that need to be combined more or less requires to keep the physical size—the molecular weight—of each element as small as possible; for instance, as small peptides or peptide-like molecules.

2. Definition of the elements of a synthetic oral vaccine

The minimal elements necessary to induce a proper immune response are B- and T-cell epitopes. B-cell epitopes are necessary to induce antibodies, T cell epitopes to switch on the immune response.

2.1. Definition of B-cell epitopes

B-cell epitopes are defined as those parts of the molecule which bind antibodies with the appropriate properties, for instance virus neutralizing activity. In the case of proteins they are between 12 and 20 amino acids long. Since multiple, partially overlapping, B-cell epitopes may be located on an antigenic site [3], it is better to use the term "antigenic site" if the object is to define an antigen which will induce the appropriate antibodies. However, for simplicity sake I shall use the term B-cell epitopes instead.

From a practical point of view B cell epitopes can be divided into three groups (Fig. 2 [4,5]):

(1) Real linear epitopes. These epitopes are easily mapped using peptides, but probably do not occur very often.
(2) Discontinuous epitopes with relative large linear parts. The linear parts of these epitopes are easily mapped using peptides. Epitopes of this group probably form a large minority of all existing epitopes.
(3) Discontinuous scattered epitopes. These epitopes probably form the majority of all existing epitopes. They are difficult to map with peptide based methods. One has to rely on methods like ‘site directed mutagenesis’, or, in the case of replicating agents, on ‘escape mutations’. Often the data will only produce a useful definition of the epitope if the spatial structure of the protein carrying the epitope is known.

The precise definition (i.e., length, core, role of individual amino acids) of epitopes of the first group is relatively straightforward, using PEPSCAN methods (Fig. 3 [4]) or other peptide-based methods. Also the reconstruction of such epitopes as synthetic peptides is relatively easy and has been shown to induce readily the appropriate antibodies or even protection [5–7]. The precise definition of parts of discontinuous epitopes with relative large linear parts is equally easy.

The precise definition of epitopes of the third
Fig. 3. Schematic representation of the PEPSCAN method. On top is shown the primary amino acid sequence of gp120 of HIV-1, the major glycoprotein of HIV-1. Each circle represents an amino acid. For the amino acids the single character code is used (i.e. A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine). The amino acid sequence of gp120 of HIV-1 is then divided into overlapping peptides, as indicated. Peptide no. 1 is the peptide which starts with amino acid no. 1 and ends with amino acid no. 9, peptide no. 2 is the peptide starting at amino acid no. 2 to amino acid no. 10, etc. The peptides are synthesized on polyethylene rods, as shown at the bottom of this picture; the peptides are indicated as —. (The rods are in such a configuration that they fit into microtiter wells; this greatly simplifies handling of the rods and data manipulation.) All rods with peptides are then contacted with the same antibody (indicated as <). Some peptides will bind this antibody. After the rods are taken out of the antibody solution and have been washed, the antibody still present on the rods (bound to the peptide) can then be tested with anti-antibody conjugate for the presence of antibody. This directly produces the sequence of the peptide which bound the antibody. After this process the antibody can be removed from the peptides and the peptides can be reused. One technician can easily test 2000 different peptides daily for reactivity with a given antibody. Over 2000 different peptides are being synthesized on a routine basis at our laboratory each month. (From Ref. 4.)

group requires different methods and such epitopes are difficult or even impossible to reconstruct as linear epitopes. Their resolution needs different approaches, for instance the use of (random) peptide libraries which would allow the definition of peptide mimics of complex conformational epitopes [8–14]. Results are promising and the first useful examples may materialize soon. Nevertheless, a significant number of peptides has been defined which readily induce antiviral, anti-bacterial, anti-parasite, anti-hormone or anti-allergen antibodies.

The viruses include: foot-and-mouth disease virus [4,15–21], paroviruses [22,23], herpes viruses [24,25], retro viruses [26–43]; corona viruses [44–50], and others [51–55]. The bacteria include: mycobacteria [56]. The parasites include: malaria, trypanosoma and chlamydia [57–63]. The hormones include: hCG and inhibin [64,65]. The allergens include: house dust mite major allergen der p II [66]; cat allergen Fel d I [67]. Others include alpha-bungarotoxins [68], fat globules [69], tumour necrosis factor-alpha [70].

Before starting to define B-cell epitopes to be used in an oral vaccine it is necessary, as discussed above, to decide which strategy (Fig. 1) will be followed. If the “encapsulated” strategy is selected, natural amino acids can be used; furthermore it may not be necessary to have all elements combined into one large molecule. If the naked molecule strategy is chosen than the epitopes have to be mapped using the same building blocks as used in the synthesis; because the use of non-natural amino acids may be
mandatory to counteract the action of proteolytic enzymes, the same amino acids have to be used for the epitope mapping (using PEPSCAN or other methods based on synthetic peptides this is hardly a problem).

2.2. Definition of T-cell epitopes

T-cell epitopes are necessary to switch on the immune response. Without T-cell epitopes poor responses, if any, are obtained. Thus T-cell epitopes must be present in a vaccine.

Preferentially T-cell epitopes should be from the same agent for which the vaccine is designed. Sometimes however T-cell epitopes can be borrowed from other proteins [6]. Pathogens normally carry numerous T-cell epitopes; it depends however on the genetic make-up of the vaccinated individual which epitope will be used [71,72]. For the development of peptide vaccines this forms an unsolved problem. Solutions are sought using “promiscuous” T-cell epitopes, i.e. epitopes that can be used by the immune system of individuals with different genetic make-up [73].

T-cell epitopes are linear peptides approximately between 9 and 15 amino acids long. Since large sets of free linear peptides can be made [74] systematic definition of T-cell epitopes, at the level of single amino acids, is equally simple and straightforward as that for linear B-cell epitopes [5]. Just as in case of B-cell epitopes one has to decide at the very beginning which strategy (Fig. 1) will be followed, because this determines how the T-cell epitopes must be mapped.

2.3. Definition of the carrier or backbone molecule

Normally protein molecules, like bovine serum albumin, ovalbumin or keyhole limpet haemocyanin, are used as carrier molecules for peptides. They provide two functions: firstly they make the peptides immunogenic due to the larger molecular weights of the peptide carrier molecule combination (peptides shorter than 18 amino acids are often non-immunogenic); secondly the carrier molecules provide the necessary T-cell epitopes to switch on the immune response.

However, for oral vaccines these carrier molecules have disadvantages. For instance they are vulnerable to proteolytic attack; furthermore if they are being encapsulated their relative bulk may be disadvantageous. In addition protein carrier molecules suffer from the general disadvantage that the linkage and exposure of the peptides coupled to the carrier molecule are ill defined.

These disadvantages could be overcome by coupling the B- and T-cell epitopes to a synthetic backbone molecule [75]. Thus multiple peptides forming B- and T-cell epitopes combined into a single molecule, have been shown to form good immunogens [76]. This approach allows the use of both natural or small synthetic building blocks and is equally well applicable in both strategies.

2.4. Definition of the immunomodulating element

The object is to switch on the appropriate immune response (local, systemic or both). Although it is not yet completely clear how this can be done, it appears that by influencing the cytokines that regulate the development of the immune response, the outcome may be influenced [77–79]. Thus the incorporation of certain cytokines, cytokine inducers or cytokine antagonists into the vaccine, may help to influence the outcome of the vaccination. The use of cytokines, especially in oral vaccine, is probably not very practical due to proteolytic attack by environmental enzymes and due to the cost. However it has recently been shown that peptides derived from cytokines may still be bioactive [80,81; unpublished observations], which would make them excellently suited to be incorporated into a vaccine. Theoretically such peptides could be made proteolysis resistant by using non-natural amino acids; the cost of such peptides would compare very favourable with the cost of whole cytokines.

2.5. Definition of the adjuvant element

Adjuvants are probably highly necessary for oral vaccines because normally the local immune
system is known to produce transient responses of short duration or even the induction of a suppressor response [82]. Unfortunately, the working mechanism of adjuvants are poorly defined. Adjuvants probably work among other things, by inducing cytokine cascades. It is therefore possible that adjuvant and immunomodulating activities overlap. It remains to be seen whether they can be separated.

Relative small molecules have been described that exert adjuvant activity [83]. One of them is a peptide derived from II-1 [84], well suited to be incorporated into a synthetic vaccine. Such synthetic molecules may be used directly mixed into the vaccine or hooked up to the backbone molecule.

2.6. Definition of a targeting element

In order to counteract the huge dilution and continuous movement of the vaccine within the alimentary tract, the encapsulated vaccine or naked vaccine molecule needs to be targeted to receptors of the appropriate cells in the gut. Unfortunately, such receptors are still ill defined. Nevertheless if such receptor binding peptides can be defined they can be exposed on the outer layer of the encapsulate vaccine or hooked on to the naked vaccine molecule. Candidate peptides could perhaps be designed as peptides which mimic the binding site of cholera toxin for its cell receptor, ganglioside GM1 [85]. Pending the development of such peptides one could use cholera toxin B subunit (CTB) as a carrier molecule [86] in case of the naked vaccine strategy. In case of the encapsulated strategy a targeting molecule may not be necessary because antigen containing microspheres, of the appropriate size and appropriate physical-chemical make-up, are taken up spontaneously by the appropriate cells in the gut, after oral ingestion [87].

3. Conclusion

The rational design of effective oral vaccines based on synthetic peptides is a very ambitious undertaking, and involves the solution of huge problems related to protection of the antigens against degradation in the alimentary tract, efficient uptake of the antigens by the relevant cells, and efficient induction of long-lasting systemic immunity, local immunity, or both.

Rational approaches need additional data with respect to the details of the antigen uptake by M cells, the mechanism by which the internalized antigens induce a response, and the mode of action of adjuvants.

On the other hand, microorganisms exist which efficiently induce immune responses via the oral route. Furthermore, systematic methods are available to define the necessary epitopes, cell attachment sites and immunostimulating molecules in the form of simple synthetic natural or non-natural peptides. Also the chemistry is being developed to combine these components into biological active degradation-resistant vaccines. Thus, oral vaccines may soon be reality, while the ultimate oral vaccine, which is cheap and stable and induces long-lasting immunity against a series of diseases after a single application, may one day be feasible as well. The speed of this development will depend on the speed by which new technology in the area of bio molecular recognition will develop, i.e. the appropriate peptide chemistry, organic chemistry, molecular modelling, resolution of the molecular interaction of key molecules in microbiology and immunology.

Acknowledgements

I would like to thank Janke de Jager for typing the manuscript.

References

[1] La Granderie, M., Murray, A., Gicquel, B., Leclerc, C. and Gheorghiu, M. (1993) Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 11, 1283–1290.

[2] Dougan, G., Hormaeche, C.E. and Maskell, D.J. (1987) Live oral Salmonella vaccines: Potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasite Immunol. 9, 151.
Small peptides induce antibodies with a sequence and structural requirements for binding antigen comparable to antibodies raised against the native protein. Proc. Natl. Acad. Sci. USA 82, 178.

[17] Meloen, R.H. and Barteling, S.J. (1986) Epitope mapping of the outer structural protein VP1 of three different serotypes of FMDV. Virology 149, 55.

[18] Meloen, R.H., Puijk, W.C. and Meijer, J.A. (1986) The use of peptides to locate epitopes on the surface of Foot-and-Mouth Disease. In: H. Peeters (Ed.), Proteins of the Biological Fluids 34, Pergamon Press, New York, p. 103.

[19] Meloen, R.H., Puijk, W.C., Meijer, J.A. (1987) Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus. J. Gen. Virol. 68, 305.

[20] Posthumus, W.P.A., Puijk, W.C., Thomas, A.A.M. and Meloen, R.H. (1991) Surface locations of foot-and-mouth disease virus type A10 epitopes of neutralizing monoclonal antibodies. In: Localization of epitopes on viral surface proteins: thesis. University of Utrecht, pp. 21–36.

[21] McCabon, D., Crowther, J.R. and Belsham, G.J. (1989) Evidence for at least four antigenic sites on type 0 foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody resistant mutants. J. Gen. Virol. 70, 639.

[22] Brown, C.S., Jensen, T. and Meloen, R.H. (1992) Localization of an immunodominant domain on baculovirus-produced parovirus B19 capsids: Correlation to a major surface region on the native virus particle. J. Virol. 66, 6989.

[23] Langeveld, J.P.M., Casal, J.I. and Vela, C. (1993) B-cell epitopes of canine parovirus: Distribution on the primary structure and exposure on the viral surface. J. Virol. 67, 765.

[24] Middeldorp, J.M. and Meloen, R.H. (1988) Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. J. Virol. Methods 21, 147.

[25] Jacobs, L., Meloen, R.H. and Rhiza, H.J. (1990) Epitope analysis of glycoprotein 1 of Pseudorabies virus. J. Gen. Virol. 71, 881.

[26] Goudsmit, J., Debouck, C. and Meloen, R.H. (1988) HIV type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85, 4478.

[27] Goudsmit, J., Meloen, R.H. and Rusche, J.R. (1988) Baculovirus expressed gp160 of HIV-1 induces antibodies with isolate-specific binding to a nine-amino acid sequence related to type-specific cell fusion inhibition. AIDS 2, 231.

[28] Krone, W.J.A., Debouck, C. and Epstein, L.G. (1988) Natural antibodies to HIV tat epitopes and expression of HIV-1 genes in vivo. J. Med. Virol. 26, 261.

[29] Goudsmit, J., Bakker, M. and Smit, L. (1989) Shared and cross reactive epitopes on peptide antigens binding HIV-1 neutralizing antibodies of susceptible hosts. In:
Vaccines 89, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 145.

[30] Goudsmit, J., Bakker, M. and Smit, L. (1989) Specificity of chimpanzee antibodies binding a strain specific HIV-1 neutralization epitope of the external envelope. J. Med. Primatol. 18, 357.

[31] Goudsmit, J., Meloen, R.H. and Brasseur, R. (1989) Human B-cell epitopes of HIV-2 transmembrane protein are similarly spaced as in HIV-1. J. AIDS 2, 297.

[32] Meloen, R.H., Liskamp, R. and Goudsmit, J. (1989) Specificity and function of the individual amino acids of a major determinant of HIV-1 that induces neutralization activity. J. Gen. Virol. 70, 1505.

[33] Boucher, C.A., Krone, W.J. and Goudsmit, J. (1990) Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30. J. Clin. Lab. Anal. 4, 43.

[34] Brake, D.A., Goudsmit, J. and Krone, W.J.A. (1990) Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1. J. Virol. 64, 962.

[35] Goudsmit, J., Meloen, R.H. and Brasseur, R. (1990) Map of sequential B-cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 31, 327.

[36] Langedijk, J.P.M., Schalken, J.J. and Tersmette, M. (1990) Location of epitopes on the major core protein p24 of the human immunodeficiency virus (HIV) J. Gen. Virol. 71, 2609.

[37] Langedijk, J.P.M., Back, N.K.T. and Durda, P.J. (1991) Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of HIV-1. J. Gen. Virol. 72, 2519.

[38] De Wolf, F., Meloen, R.H. and Bakker, M. (1991) Characterization of human antibody binding sites on the external envelope of human immunodeficiency virus type 2. J. Gen. Virol. 72, 1261.

[39] Zwart, G., Langedijk, H. and Van der Hock, L. (1991) Immunodominance and Antigenic Variation of the Principal Neutralization Domain of HIV-1. Virology 181, 481.

[40] Javaherian, K., Langlois, A.J. and Schmidt, S. (1992) The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 89, 1418.

[41] Langedijk, J.P.M., Back, N.K.T. and Kinney-Thomas, E. (1992) Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Arch. Virol. 126, 129.

[42] Langedijk, J.P.M., Vos, W.F.H.M. and Van Doornum, G.J.J. (1992) Identification of cross-reactive epitopes recognized by HIV-1 false-positive sera. AIDS 6, 1547.

[43] D’Souza, M.P., Durda, P. and Hanson, C.V. (1991) Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. AIDS 5, 1061.

[44] Kusters, J.G., Jager, E.J. and Lenstra, J.A. (1989) Analysis of an immunodominant region of avian coronavirus IBV. J. Immunol. 143, 2692.

[45] Lutjies, W., Geerts, D. and Posthumus, W. (1989) Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses. J. Virol. 63, 1408.

[46] Bredenbeck, P.J., Snijder, E.J., Noten, A.F.H., Den Boon, J.A., Schaeper, W.M.M., Horzinek, M.C. and Spaan, W.J.M. (1990) The polymerase gene of corona- and toroviruses: evidence for an evolutionary relationship. In: D. Cavanagh and T.D.K. Brown (Eds), Pathogenesis and Molecular Biology of Coronaviruses. Plenum Press, New York–Adv. Exp. Med. Biol. 276, 307–316.

[47] Enjuanes, L., Gebauer, F. and Correa, I. (1990) Location of antigenic sites of the S-glycoprotein of transmissible gastroenteritis virus and their conservation in coronaviruses. In: D. Cavanagh and T.D.K. Brown (Eds), Pathogenesis and Molecular Biology of Coronaviruses. Plenum Press, New York–Adv. Exp. Med. Biol. 276, 159.

[48] Posthumus, W.P.A., Lenstra, J.A. and Schaaper, W.M.M. (1990) Analysis and simulation of a neutralizing epitope of transmissible gastroenteritis virus. J. Virol. 64, 3301.

[49] Posthumus, W.P.A., Meloen, R.H. and Enjuanes, L. (1990) Linear neutralizing epitopes on the peplomer protein of coronaviruses. In: D. Cavanagh and T.D.K. Brown (Eds), Pathogenesis and Molecular Biology of Coronaviruses. Plenum Press, New York–Adv. Exp. Med. Biol. 276, 181.

[50] Gebauer, F., Posthumus, W.P.A. and Correa, I. (1991) Residues involved in the antigenic sites of transmissible gastroenteritis coronavirus S glycoprotein. Virology 183, 225.

[51] Versteeg-van Oosten, J., Langeveld, S. and Voorma, H.O. (1989) Epitope Mapping of the fusion protein of measles virus. In: Vaccines 89, Cold Spring Harbor Laboratory. Cold Spring Harbor, NY, p. 521.

[52] Coursaget, P., Lesage, G. and Le Cann, P. (1991) Mapping of linear B-cell epitopes of hepatitis B surface antigen. Virology 142, 461.

[53] Snijders, A., Benaissa-Trouw, B.J. and Oosterlaken, T.A.M. (1991) Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J. Gen. Virol. 72, 557.

[54] Chassot, S., Lambert, V. and Kay, A. (1993) Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides. Virology 192, 217.

[55] Gonzalez, R.A., Sanchez, J., Holmgren, J., Lopez, S. and Arias, C.F. (1993) Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit. Gene 133, 227–232.

[56] Radford, A.J., Wood, P.R. and Billman-Jacobsc, H. (1990) Epitope mapping of the Mycobacterium bovis secretary protein MPB70 using overlapping peptide analysis. J. Gen. Microbiol. 136, 265.

[57] Van Amerongen, A., Sauerwein, R.W. and Beckers, P.J.A. (1989) Identification of a peptide sequence of the
25 kD surface protein of *Plasmodium falciparum* recognized by transmission-blocking monoclonal antibodies: implications for synthetic vaccine development. Parasite Immunol. 11, 425.

[58] Van Amerongen, A., Meloen, R.H. and Beckers, P.J.A. (1990) PEPSI Scan based amino acid modifications of a *P. falciparum* pfs25 peptide sequence substantially increased reactivity with transmission blocking monoclonal antibodies. In: Vaccines 90, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, p. 461.

[59] Stüber, D., Bannwarth, W. and Pink, J.R.L. (1990) New B cell epitopes in the *Plasmodium falciparum* malaria circumsporozoite protein. Eur. J. Immunol. 20, 819.

[60] Van Amerongen, A., Beekers, P.J.A. and Plasman, H.H. (1992) Peptides reactive with a transmission blocking monoclonal antibody against *Plasmodium falciparum* Pfs25. 2000-fold affinity increase by PEPSI Scan-based amino acid substitutions. Peptide Res. 5, 269.

[61] Clarke, J.L., Drake, A.F. and Vallance, G.R. (1990) Pepsic and circular-dishroism analysis of a repetitive antigen of *Trypanosoma cruzi*. Biochem. Soc. Trans. 18, 868.

[62] Ahlborg, N., Berezins, K. and Perlmann, P. (1991) Definition of the epitope recognized by the *Plasmodium falciparum*-reactive human monoclonal antibody 3SG2. Mol. Biochem. Parasitol. 46, 89.

[63] Miles, M.A., Wallace, G.R. and Clarke, J.L. (1989) Multiple peptide synthesis (Pepscan method) for the systematic analysis of B- and T-cell epitopes: application to parasite proteins. Parasitol. Today 5, 397.

[64] Grootenhuis, A.J., Steenbergen, J. and Timmerman, M.A. (1989) Inhibin and activin-like activity in fluids from male and female gonads: different molecular weight forms and bioactivity/immunoreactivity ratios. J. Endocrinol. 122, 293.

[65] Van Amerongen, A., Plasman, H.H. and Kuperus, D. (1994) Design of peptides with improved affinities for anti-human chonic gonadotropin monoclonal antibodies. Peptide Res. 7, 83–90.

[66] Van ‘t Hof, W., Driedijk, P.C. and Beck-Sickinger, A.G. (1991) Epitope mapping of the *Dermatophagoides pteronyssinus* house dust mite major allergen Der p II using overlapping synthetic peptides. Mol. Immunol. 28, 1225.

[67] Van Millegen, F.J., Van ‘t Hof, W., Van den Berg, M. and Aalberse, R.C. (1994) IgE epitopes on the cat (*Felis domesticus*) major allergen Fel d 1: a study with overlapping synthetic peptides. J. Allergy Clin. Immunol. 93, 34–43.

[68] Tzartos, S.J. and Remoundos, M.S. (1990) Fine localization of the major alpha-bungarotoxin binding site to residues alpha 189–195 of the *Torpedo* acetylcholine receptor. Residues 189, 190 and 195 are indispensable for binding. J. Biol. Chem. 265, 21462.

[69] Xing, P.X., Reynolds, K. and Pietersz, G.A. (1991) Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions. Immunology 72, 304.

[70] Steemer, R.H., Gausepohl, H. and Mirshahi, M. (1992) Immunological characterization of an immunomodulatory epitope in S-antigen/arterin with a sequence motif common to tumor necrosis factor alpha. Immunol. Lett. 32, 233.

[71] Germain, R.N. (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287–299.

[72] Van Lierop, M.J.C., Van Noort, J.M., Wagenaar, J.P.A., Rutten, V.P.M.G., Langeveld, J.P.M., Meloen, R.H. and Hensen, E.J. (1994) T-cell stimulatory fragments of foot-and-mouth disease virus released by mild treatment with cathepsin, D. J. Gen. Virol. 75, 2937–2946.

[73] Van Lierop, M.J.C., Wagenaar, J.P.A., Van Noort, J.M. and Hensen, E.J. (1995) Sequences derived from the highly antigenic VP1 region 140–160 of Foot-and-mouth disease virus do not prime for a Bovine T-cell response against intact virus. J. Virol. 69, 2782–2786.

[74] Van der Zee, R., Van Eden, W., Meloen, R.H., Noordzij, A. and Van Embden, J.D.A. (1989) Efficient mapping and characterization of a T-cell epitope by the simultaneous synthesis of multiple peptides. Eur. J. Immunol. 19, 43–47.

[75] Halimi, H. and Rivaille, P. (1993) Immune response related to the molecular structure of a peptide from the cholera toxin β subunit. Vaccine 11, 1233–1239.

[76] Calvo-Calle, J.M., De Oliveira, G.A., Clavijo, P., Maracic, M., Tam, J.P., Lu, Y.A., Nardin, E.H., Nussenzweig, R.S. and Cochrane, A.H. (1993) Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of *Plasmodium falciparum*. J. Immunol., 150, 1403–1412.

[77] Hermanek, J., Goyal, P.K. and Wakelin, D. (1994) Lymphocyte, antibody and cytokine responses during concurrent infections between helminths that selectively promote T-helper-1 or T-helper-2 activity. Parasite Immunol. 16, 111–117.

[78] Ramsay, A.J. and Kohonen-Corish, M. (1993) Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur. J. Immunol. 23, 3141–3145.

[79] Bomford, R., Stapleton, M., Winsor, S., McKnight, A. and Andronova, T. (1992) The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Hum. Retroviruses 8, 1763–1771.

[80] Shch, L., Lin, H.H., Jeng, K.C. and Chen, C.F. (1993) Studies of the synthesis, immunology, and cytotoxicity of a cyclic octapeptide corresponding to TNF-alpha-(59–66) J. Med. Chem. 36, 4302–4307.

[81] Jones, C.M., Reyes, C.J., Cook, R.G., Kruvy, G.A. and Rosevvar, P.R. (1994) Synthetic macrophage activating peptides derived from the N-terminus of human MCF. Biochem. Biophys. Res. Commun. 199, 20–25.

[82] Husband, A.J. (1993) Novel vaccination strategies for the control of mucosal infection. Vaccine 11, 107–112.

[83] Burroughs, M., Rozdzinski, E., Geelen, S. and Tuomanen, E. (1993) A structure-activity relationship for induction of meningeal inflammation by muramyl peptides. J. Clin. Invest. 92, 297–302.
[84] Tagliabuc, A. and Boraschi, D. (1993) Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163–171. Vaccine 11, 594–595.

[85] Orlandi, P.A. and Fishman, P.H. (1993) Orientation of cholera toxin bound to target cells. J. Biol. Chem. 268, 17038–17044.

[86] Dertzbauch, M.T. and Elson, C.O. (1993) Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 61, 48–55.

[87] Morris, W., Steinhoff, M.C. and Russell, P.K. (1994) Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12, 5–11.